Try our beta test site

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2015 by Immunomedics, Inc..
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Immunomedics, Inc.
ClinicalTrials.gov Identifier:
NCT01510561
First received: January 5, 2012
Last updated: February 12, 2015
Last verified: February 2015